nodes	percent_of_prediction	percent_of_DWPC	metapath
Loxapine—HTR1D—meninx—melanoma	0.0381	0.202	CbGeAlD
Loxapine—DRD5—eyelid—melanoma	0.0345	0.182	CbGeAlD
Loxapine—CHRM5—skin epidermis—melanoma	0.00967	0.0511	CbGeAlD
Loxapine—Clobazam—SLC6A11—melanoma	0.00888	0.702	CrCbGaD
Loxapine—HTR5A—head—melanoma	0.00668	0.0353	CbGeAlD
Loxapine—HTR2A—hindlimb—melanoma	0.0045	0.0238	CbGeAlD
Loxapine—HTR1B—blood vessel—melanoma	0.00446	0.0236	CbGeAlD
Loxapine—HTR1D—blood vessel—melanoma	0.00432	0.0229	CbGeAlD
Loxapine—Photosensitivity—Vemurafenib—melanoma	0.00429	0.0196	CcSEcCtD
Loxapine—HTR2A—appendage—melanoma	0.00386	0.0204	CbGeAlD
Loxapine—Chest tightness—Docetaxel—melanoma	0.00376	0.0172	CcSEcCtD
Loxapine—HTR7—endothelium—melanoma	0.00373	0.0198	CbGeAlD
Loxapine—Extrapyramidal disorder—Temozolomide—melanoma	0.00352	0.0161	CcSEcCtD
Loxapine—HTR7—blood vessel—melanoma	0.00344	0.0182	CbGeAlD
Loxapine—CHRM5—eye—melanoma	0.00344	0.0182	CbGeAlD
Loxapine—Menstruation irregular—Docetaxel—melanoma	0.00319	0.0146	CcSEcCtD
Loxapine—Liver injury—Temozolomide—melanoma	0.00315	0.0144	CcSEcCtD
Loxapine—HRH2—skin of body—melanoma	0.00313	0.0166	CbGeAlD
Loxapine—Wheezing—Bleomycin—melanoma	0.00305	0.014	CcSEcCtD
Loxapine—Amenorrhoea—Temozolomide—melanoma	0.00302	0.0138	CcSEcCtD
Loxapine—CHRM5—skin of body—melanoma	0.00299	0.0158	CbGeAlD
Loxapine—Photosensitivity reaction—Vemurafenib—melanoma	0.00297	0.0136	CcSEcCtD
Loxapine—Weight decreased—Vemurafenib—melanoma	0.00295	0.0135	CcSEcCtD
Loxapine—HTR1E—head—melanoma	0.00285	0.0151	CbGeAlD
Loxapine—Gait disturbance—Carmustine—melanoma	0.00281	0.0128	CcSEcCtD
Loxapine—Gait disturbance—Temozolomide—melanoma	0.00272	0.0124	CcSEcCtD
Loxapine—CHRM4—head—melanoma	0.0025	0.0132	CbGeAlD
Loxapine—HTR7—neck—melanoma	0.00246	0.013	CbGeAlD
Loxapine—Gynaecomastia—Carmustine—melanoma	0.00246	0.0112	CcSEcCtD
Loxapine—Dry eye—Temozolomide—melanoma	0.00245	0.0112	CcSEcCtD
Loxapine—Angiopathy—Vemurafenib—melanoma	0.00236	0.0108	CcSEcCtD
Loxapine—Mediastinal disorder—Vemurafenib—melanoma	0.00235	0.0107	CcSEcCtD
Loxapine—Cerebrovascular accident—Bleomycin—melanoma	0.00233	0.0106	CcSEcCtD
Loxapine—HTR2A—endothelium—melanoma	0.00233	0.0123	CbGeAlD
Loxapine—DRD3—head—melanoma	0.00232	0.0123	CbGeAlD
Loxapine—Alopecia—Vemurafenib—melanoma	0.0023	0.0105	CcSEcCtD
Loxapine—HTR1D—eye—melanoma	0.0023	0.0122	CbGeAlD
Loxapine—HTR6—head—melanoma	0.00224	0.0118	CbGeAlD
Loxapine—Dysgeusia—Vemurafenib—melanoma	0.00222	0.0102	CcSEcCtD
Loxapine—DRD5—head—melanoma	0.00218	0.0115	CbGeAlD
Loxapine—HTR2A—blood vessel—melanoma	0.00215	0.0114	CbGeAlD
Loxapine—Nasal congestion—Temozolomide—melanoma	0.00211	0.00966	CcSEcCtD
Loxapine—HRH2—head—melanoma	0.00205	0.0108	CbGeAlD
Loxapine—Amenorrhoea—Docetaxel—melanoma	0.00201	0.00917	CcSEcCtD
Loxapine—Chest discomfort—Docetaxel—melanoma	0.00199	0.00911	CcSEcCtD
Loxapine—Cough—Vemurafenib—melanoma	0.00198	0.00904	CcSEcCtD
Loxapine—CHRM5—head—melanoma	0.00195	0.0103	CbGeAlD
Loxapine—Bronchospasm—Bleomycin—melanoma	0.00194	0.00887	CcSEcCtD
Loxapine—Dysphagia—Dactinomycin—melanoma	0.00184	0.00841	CcSEcCtD
Loxapine—Nervous system disorder—Vemurafenib—melanoma	0.00182	0.0083	CcSEcCtD
Loxapine—ADRA1B—head—melanoma	0.00179	0.00945	CbGeAlD
Loxapine—Weight decreased—Bleomycin—melanoma	0.00178	0.00815	CcSEcCtD
Loxapine—Hepatocellular injury—Docetaxel—melanoma	0.00176	0.00806	CcSEcCtD
Loxapine—DRD2—eye—melanoma	0.00173	0.00916	CbGeAlD
Loxapine—Hypotension—Vemurafenib—melanoma	0.00173	0.0079	CcSEcCtD
Loxapine—Dysphagia—Carmustine—melanoma	0.00172	0.00787	CcSEcCtD
Loxapine—DRD2—retina—melanoma	0.00172	0.00908	CbGeAlD
Loxapine—DRD1—head—melanoma	0.00166	0.00881	CbGeAlD
Loxapine—Dysphagia—Temozolomide—melanoma	0.00166	0.0076	CcSEcCtD
Loxapine—HTR3A—head—melanoma	0.00161	0.0085	CbGeAlD
Loxapine—Gastrointestinal disorder—Vemurafenib—melanoma	0.0016	0.0073	CcSEcCtD
Loxapine—Fatigue—Vemurafenib—melanoma	0.0016	0.00729	CcSEcCtD
Loxapine—Constipation—Vemurafenib—melanoma	0.00158	0.00723	CcSEcCtD
Loxapine—Lightheadedness—Docetaxel—melanoma	0.00158	0.00721	CcSEcCtD
Loxapine—Hypoaesthesia—Bleomycin—melanoma	0.00157	0.00718	CcSEcCtD
Loxapine—HTR2A—neck—melanoma	0.00154	0.00813	CbGeAlD
Loxapine—Agranulocytosis—Dactinomycin—melanoma	0.00153	0.00699	CcSEcCtD
Loxapine—Photosensitivity reaction—Temozolomide—melanoma	0.00152	0.00694	CcSEcCtD
Loxapine—Weight increased—Temozolomide—melanoma	0.00151	0.00692	CcSEcCtD
Loxapine—Renal failure—Carmustine—melanoma	0.00151	0.0069	CcSEcCtD
Loxapine—Weight decreased—Temozolomide—melanoma	0.00151	0.00688	CcSEcCtD
Loxapine—Hepatitis—Dactinomycin—melanoma	0.00147	0.00673	CcSEcCtD
Loxapine—HRH2—lymph node—melanoma	0.00143	0.00758	CbGeAlD
Loxapine—Alopecia—Bleomycin—melanoma	0.00139	0.00637	CcSEcCtD
Loxapine—Hypoaesthesia—Carmustine—melanoma	0.00137	0.00627	CcSEcCtD
Loxapine—HRH1—eye—melanoma	0.00137	0.00724	CbGeAlD
Loxapine—Hypersensitivity—Vemurafenib—melanoma	0.00136	0.00623	CcSEcCtD
Loxapine—HTR1B—head—melanoma	0.00135	0.00714	CbGeAlD
Loxapine—CHRM2—head—melanoma	0.00134	0.0071	CbGeAlD
Loxapine—SLC6A3—head—melanoma	0.00134	0.00708	CbGeAlD
Loxapine—ADRA2C—mammalian vulva—melanoma	0.00134	0.00707	CbGeAlD
Loxapine—Hepatitis—Temozolomide—melanoma	0.00133	0.00609	CcSEcCtD
Loxapine—Asthenia—Vemurafenib—melanoma	0.00133	0.00607	CcSEcCtD
Loxapine—Hypoaesthesia—Temozolomide—melanoma	0.00132	0.00605	CcSEcCtD
Loxapine—Pruritus—Vemurafenib—melanoma	0.00131	0.00598	CcSEcCtD
Loxapine—HTR1D—head—melanoma	0.00131	0.00691	CbGeAlD
Loxapine—Alopecia—Dactinomycin—melanoma	0.0013	0.00595	CcSEcCtD
Loxapine—HTR2C—head—melanoma	0.00129	0.00684	CbGeAlD
Loxapine—ADRB1—head—melanoma	0.00127	0.00671	CbGeAlD
Loxapine—Leukopenia—Bleomycin—melanoma	0.00123	0.00562	CcSEcCtD
Loxapine—SLC6A4—head—melanoma	0.00123	0.00648	CbGeAlD
Loxapine—Dizziness—Vemurafenib—melanoma	0.00122	0.00559	CcSEcCtD
Loxapine—CHRM1—head—melanoma	0.00122	0.00646	CbGeAlD
Loxapine—Alopecia—Carmustine—melanoma	0.00122	0.00556	CcSEcCtD
Loxapine—Angiopathy—Temozolomide—melanoma	0.00121	0.00552	CcSEcCtD
Loxapine—Mediastinal disorder—Temozolomide—melanoma	0.0012	0.00548	CcSEcCtD
Loxapine—Cough—Bleomycin—melanoma	0.0012	0.00548	CcSEcCtD
Loxapine—Vomiting—Vemurafenib—melanoma	0.00118	0.00538	CcSEcCtD
Loxapine—Alopecia—Temozolomide—melanoma	0.00118	0.00538	CcSEcCtD
Loxapine—Chest pain—Bleomycin—melanoma	0.00117	0.00535	CcSEcCtD
Loxapine—Orthostatic hypotension—Docetaxel—melanoma	0.00117	0.00534	CcSEcCtD
Loxapine—Rash—Vemurafenib—melanoma	0.00117	0.00533	CcSEcCtD
Loxapine—Dermatitis—Vemurafenib—melanoma	0.00117	0.00533	CcSEcCtD
Loxapine—Headache—Vemurafenib—melanoma	0.00116	0.0053	CcSEcCtD
Loxapine—Leukopenia—Dactinomycin—melanoma	0.00115	0.00524	CcSEcCtD
Loxapine—HTR2A—eye—melanoma	0.00114	0.00604	CbGeAlD
Loxapine—Dysgeusia—Temozolomide—melanoma	0.00114	0.00519	CcSEcCtD
Loxapine—HTR2A—retina—melanoma	0.00113	0.00599	CbGeAlD
Loxapine—Confusional state—Bleomycin—melanoma	0.00113	0.00517	CcSEcCtD
Loxapine—Vision blurred—Carmustine—melanoma	0.00113	0.00517	CcSEcCtD
Loxapine—Tremor—Carmustine—melanoma	0.00112	0.00514	CcSEcCtD
Loxapine—Oedema—Bleomycin—melanoma	0.00112	0.00513	CcSEcCtD
Loxapine—Dysphagia—Docetaxel—melanoma	0.00111	0.00506	CcSEcCtD
Loxapine—Agitation—Carmustine—melanoma	0.0011	0.00504	CcSEcCtD
Loxapine—Nausea—Vemurafenib—melanoma	0.0011	0.00502	CcSEcCtD
Loxapine—Thrombocytopenia—Bleomycin—melanoma	0.0011	0.00502	CcSEcCtD
Loxapine—CHRM3—head—melanoma	0.00109	0.00578	CbGeAlD
Loxapine—Vision blurred—Temozolomide—melanoma	0.00109	0.00499	CcSEcCtD
Loxapine—Bronchospasm—Docetaxel—melanoma	0.00109	0.00497	CcSEcCtD
Loxapine—HTR1A—head—melanoma	0.00109	0.00576	CbGeAlD
Loxapine—Tremor—Temozolomide—melanoma	0.00109	0.00496	CcSEcCtD
Loxapine—HRH1—mammalian vulva—melanoma	0.00109	0.00574	CbGeAlD
Loxapine—SLC6A2—head—melanoma	0.00108	0.00571	CbGeAlD
Loxapine—Leukopenia—Carmustine—melanoma	0.00107	0.00491	CcSEcCtD
Loxapine—ADRA2A—mammalian vulva—melanoma	0.00107	0.00564	CbGeAlD
Loxapine—Agitation—Temozolomide—melanoma	0.00107	0.00487	CcSEcCtD
Loxapine—Hypotension—Bleomycin—melanoma	0.00105	0.00479	CcSEcCtD
Loxapine—Oedema—Dactinomycin—melanoma	0.00105	0.00478	CcSEcCtD
Loxapine—HTR7—head—melanoma	0.00104	0.0055	CbGeAlD
Loxapine—Convulsion—Carmustine—melanoma	0.00104	0.00475	CcSEcCtD
Loxapine—Leukopenia—Temozolomide—melanoma	0.00104	0.00474	CcSEcCtD
Loxapine—Hypertension—Carmustine—melanoma	0.00104	0.00473	CcSEcCtD
Loxapine—Thrombocytopenia—Dactinomycin—melanoma	0.00102	0.00468	CcSEcCtD
Loxapine—Chest pain—Carmustine—melanoma	0.00102	0.00467	CcSEcCtD
Loxapine—Cough—Temozolomide—melanoma	0.00101	0.00462	CcSEcCtD
Loxapine—Paraesthesia—Bleomycin—melanoma	0.00101	0.0046	CcSEcCtD
Loxapine—Weight increased—Docetaxel—melanoma	0.00101	0.0046	CcSEcCtD
Loxapine—Convulsion—Temozolomide—melanoma	0.001	0.00459	CcSEcCtD
Loxapine—ADRA1A—head—melanoma	0.001	0.00531	CbGeAlD
Loxapine—Weight decreased—Docetaxel—melanoma	0.001	0.00457	CcSEcCtD
Loxapine—Hypertension—Temozolomide—melanoma	0.001	0.00457	CcSEcCtD
Loxapine—Dyspnoea—Bleomycin—melanoma	0.001	0.00457	CcSEcCtD
Loxapine—Confusional state—Carmustine—melanoma	0.000987	0.00451	CcSEcCtD
Loxapine—DRD2—head—melanoma	0.000983	0.0052	CbGeAlD
Loxapine—Oedema—Carmustine—melanoma	0.000979	0.00447	CcSEcCtD
Loxapine—Renal failure—Docetaxel—melanoma	0.00097	0.00443	CcSEcCtD
Loxapine—Dry mouth—Temozolomide—melanoma	0.000965	0.00441	CcSEcCtD
Loxapine—Jaundice—Docetaxel—melanoma	0.000962	0.00439	CcSEcCtD
Loxapine—Thrombocytopenia—Carmustine—melanoma	0.000959	0.00438	CcSEcCtD
Loxapine—ADRA2C—head—melanoma	0.000956	0.00506	CbGeAlD
Loxapine—Tachycardia—Carmustine—melanoma	0.000955	0.00437	CcSEcCtD
Loxapine—Confusional state—Temozolomide—melanoma	0.000954	0.00436	CcSEcCtD
Loxapine—Oedema—Temozolomide—melanoma	0.000946	0.00432	CcSEcCtD
Loxapine—Nervous system disorder—Temozolomide—melanoma	0.000928	0.00424	CcSEcCtD
Loxapine—Thrombocytopenia—Temozolomide—melanoma	0.000926	0.00423	CcSEcCtD
Loxapine—Feeling abnormal—Bleomycin—melanoma	0.000924	0.00422	CcSEcCtD
Loxapine—Agranulocytosis—Docetaxel—melanoma	0.000921	0.00421	CcSEcCtD
Loxapine—Hypotension—Carmustine—melanoma	0.000915	0.00418	CcSEcCtD
Loxapine—Fatigue—Dactinomycin—melanoma	0.000902	0.00412	CcSEcCtD
Loxapine—Hepatitis—Docetaxel—melanoma	0.000886	0.00405	CcSEcCtD
Loxapine—Insomnia—Carmustine—melanoma	0.000885	0.00405	CcSEcCtD
Loxapine—Hypoaesthesia—Docetaxel—melanoma	0.000881	0.00403	CcSEcCtD
Loxapine—Paraesthesia—Carmustine—melanoma	0.000879	0.00402	CcSEcCtD
Loxapine—Dyspnoea—Carmustine—melanoma	0.000873	0.00399	CcSEcCtD
Loxapine—Somnolence—Carmustine—melanoma	0.00087	0.00398	CcSEcCtD
Loxapine—Feeling abnormal—Dactinomycin—melanoma	0.000862	0.00394	CcSEcCtD
Loxapine—Insomnia—Temozolomide—melanoma	0.000856	0.00391	CcSEcCtD
Loxapine—Paraesthesia—Temozolomide—melanoma	0.00085	0.00388	CcSEcCtD
Loxapine—Gastrointestinal disorder—Carmustine—melanoma	0.000845	0.00386	CcSEcCtD
Loxapine—Dyspnoea—Temozolomide—melanoma	0.000843	0.00385	CcSEcCtD
Loxapine—Somnolence—Temozolomide—melanoma	0.000841	0.00384	CcSEcCtD
Loxapine—Constipation—Carmustine—melanoma	0.000837	0.00383	CcSEcCtD
Loxapine—Hypersensitivity—Bleomycin—melanoma	0.000826	0.00378	CcSEcCtD
Loxapine—Gastrointestinal disorder—Temozolomide—melanoma	0.000817	0.00373	CcSEcCtD
Loxapine—Fatigue—Temozolomide—melanoma	0.000816	0.00373	CcSEcCtD
Loxapine—Constipation—Temozolomide—melanoma	0.000809	0.0037	CcSEcCtD
Loxapine—Feeling abnormal—Carmustine—melanoma	0.000807	0.00369	CcSEcCtD
Loxapine—Asthenia—Bleomycin—melanoma	0.000805	0.00368	CcSEcCtD
Loxapine—Angiopathy—Docetaxel—melanoma	0.000803	0.00367	CcSEcCtD
Loxapine—Mediastinal disorder—Docetaxel—melanoma	0.000798	0.00365	CcSEcCtD
Loxapine—Pruritus—Bleomycin—melanoma	0.000793	0.00363	CcSEcCtD
Loxapine—Alopecia—Docetaxel—melanoma	0.000783	0.00358	CcSEcCtD
Loxapine—Feeling abnormal—Temozolomide—melanoma	0.00078	0.00356	CcSEcCtD
Loxapine—HRH1—head—melanoma	0.000776	0.00411	CbGeAlD
Loxapine—Hypersensitivity—Dactinomycin—melanoma	0.000771	0.00352	CcSEcCtD
Loxapine—ADRA2A—head—melanoma	0.000763	0.00404	CbGeAlD
Loxapine—SLC6A2—lymph node—melanoma	0.000755	0.004	CbGeAlD
Loxapine—Dysgeusia—Docetaxel—melanoma	0.000755	0.00345	CcSEcCtD
Loxapine—Asthenia—Dactinomycin—melanoma	0.00075	0.00343	CcSEcCtD
Loxapine—Muscle spasms—Docetaxel—melanoma	0.000741	0.00339	CcSEcCtD
Loxapine—Hypersensitivity—Carmustine—melanoma	0.000721	0.0033	CcSEcCtD
Loxapine—Vomiting—Bleomycin—melanoma	0.000713	0.00326	CcSEcCtD
Loxapine—Rash—Bleomycin—melanoma	0.000707	0.00323	CcSEcCtD
Loxapine—Dermatitis—Bleomycin—melanoma	0.000706	0.00323	CcSEcCtD
Loxapine—Asthenia—Carmustine—melanoma	0.000702	0.00321	CcSEcCtD
Loxapine—Hypersensitivity—Temozolomide—melanoma	0.000697	0.00319	CcSEcCtD
Loxapine—Syncope—Docetaxel—melanoma	0.000691	0.00316	CcSEcCtD
Loxapine—Leukopenia—Docetaxel—melanoma	0.00069	0.00315	CcSEcCtD
Loxapine—Asthenia—Temozolomide—melanoma	0.000679	0.0031	CcSEcCtD
Loxapine—Loss of consciousness—Docetaxel—melanoma	0.000678	0.0031	CcSEcCtD
Loxapine—Cough—Docetaxel—melanoma	0.000673	0.00307	CcSEcCtD
Loxapine—Pruritus—Temozolomide—melanoma	0.000669	0.00306	CcSEcCtD
Loxapine—ADRA2C—lymph node—melanoma	0.000669	0.00354	CbGeAlD
Loxapine—Convulsion—Docetaxel—melanoma	0.000668	0.00305	CcSEcCtD
Loxapine—Nausea—Bleomycin—melanoma	0.000666	0.00304	CcSEcCtD
Loxapine—Hypertension—Docetaxel—melanoma	0.000666	0.00304	CcSEcCtD
Loxapine—Vomiting—Dactinomycin—melanoma	0.000665	0.00304	CcSEcCtD
Loxapine—Rash—Dactinomycin—melanoma	0.00066	0.00301	CcSEcCtD
Loxapine—Chest pain—Docetaxel—melanoma	0.000656	0.003	CcSEcCtD
Loxapine—HTR2A—head—melanoma	0.000648	0.00343	CbGeAlD
Loxapine—Dizziness—Carmustine—melanoma	0.000647	0.00296	CcSEcCtD
Loxapine—Dry mouth—Docetaxel—melanoma	0.000642	0.00293	CcSEcCtD
Loxapine—Clozapine—CYP1B1—melanoma	0.000642	0.0507	CrCbGaD
Loxapine—Confusional state—Docetaxel—melanoma	0.000634	0.0029	CcSEcCtD
Loxapine—Oedema—Docetaxel—melanoma	0.000629	0.00288	CcSEcCtD
Loxapine—Dizziness—Temozolomide—melanoma	0.000626	0.00286	CcSEcCtD
Loxapine—Vomiting—Carmustine—melanoma	0.000622	0.00284	CcSEcCtD
Loxapine—Nausea—Dactinomycin—melanoma	0.000621	0.00284	CcSEcCtD
Loxapine—Shock—Docetaxel—melanoma	0.000619	0.00283	CcSEcCtD
Loxapine—Rash—Carmustine—melanoma	0.000617	0.00282	CcSEcCtD
Loxapine—Nervous system disorder—Docetaxel—melanoma	0.000617	0.00282	CcSEcCtD
Loxapine—Dermatitis—Carmustine—melanoma	0.000617	0.00282	CcSEcCtD
Loxapine—Thrombocytopenia—Docetaxel—melanoma	0.000616	0.00281	CcSEcCtD
Loxapine—Tachycardia—Docetaxel—melanoma	0.000614	0.00281	CcSEcCtD
Loxapine—Headache—Carmustine—melanoma	0.000613	0.0028	CcSEcCtD
Loxapine—Vomiting—Temozolomide—melanoma	0.000602	0.00275	CcSEcCtD
Loxapine—Rash—Temozolomide—melanoma	0.000597	0.00273	CcSEcCtD
Loxapine—Dermatitis—Temozolomide—melanoma	0.000596	0.00272	CcSEcCtD
Loxapine—Headache—Temozolomide—melanoma	0.000593	0.00271	CcSEcCtD
Loxapine—Hypotension—Docetaxel—melanoma	0.000588	0.00269	CcSEcCtD
Loxapine—Nausea—Carmustine—melanoma	0.000581	0.00266	CcSEcCtD
Loxapine—Insomnia—Docetaxel—melanoma	0.000569	0.0026	CcSEcCtD
Loxapine—Paraesthesia—Docetaxel—melanoma	0.000565	0.00258	CcSEcCtD
Loxapine—Nausea—Temozolomide—melanoma	0.000562	0.00257	CcSEcCtD
Loxapine—Dyspnoea—Docetaxel—melanoma	0.000561	0.00256	CcSEcCtD
Loxapine—Somnolence—Docetaxel—melanoma	0.000559	0.00256	CcSEcCtD
Loxapine—HRH1—lymph node—melanoma	0.000544	0.00288	CbGeAlD
Loxapine—Gastrointestinal disorder—Docetaxel—melanoma	0.000543	0.00248	CcSEcCtD
Loxapine—Fatigue—Docetaxel—melanoma	0.000542	0.00248	CcSEcCtD
Loxapine—Constipation—Docetaxel—melanoma	0.000538	0.00246	CcSEcCtD
Loxapine—ADRA2A—lymph node—melanoma	0.000534	0.00283	CbGeAlD
Loxapine—Feeling abnormal—Docetaxel—melanoma	0.000518	0.00237	CcSEcCtD
Loxapine—Hypersensitivity—Docetaxel—melanoma	0.000464	0.00212	CcSEcCtD
Loxapine—Asthenia—Docetaxel—melanoma	0.000451	0.00206	CcSEcCtD
Loxapine—Pruritus—Docetaxel—melanoma	0.000445	0.00203	CcSEcCtD
Loxapine—Dizziness—Docetaxel—melanoma	0.000416	0.0019	CcSEcCtD
Loxapine—Azelastine—ABCB1—melanoma	0.000411	0.0325	CrCbGaD
Loxapine—Vomiting—Docetaxel—melanoma	0.0004	0.00183	CcSEcCtD
Loxapine—Rash—Docetaxel—melanoma	0.000397	0.00181	CcSEcCtD
Loxapine—Dermatitis—Docetaxel—melanoma	0.000396	0.00181	CcSEcCtD
Loxapine—Headache—Docetaxel—melanoma	0.000394	0.0018	CcSEcCtD
Loxapine—Nausea—Docetaxel—melanoma	0.000374	0.00171	CcSEcCtD
Loxapine—Olanzapine—ALB—melanoma	0.00037	0.0292	CrCbGaD
Loxapine—Olanzapine—ABCB1—melanoma	0.000353	0.0279	CrCbGaD
Loxapine—Trazodone—ABCB1—melanoma	0.000341	0.0269	CrCbGaD
Loxapine—Thiothixene—ALB—melanoma	0.000335	0.0264	CrCbGaD
Loxapine—Clobazam—ABCB1—melanoma	0.000319	0.0252	CrCbGaD
Loxapine—Trifluoperazine—ABCB1—melanoma	0.000221	0.0174	CrCbGaD
Loxapine—Quetiapine—ABCB1—melanoma	0.000214	0.0169	CrCbGaD
Loxapine—Diazepam—ALB—melanoma	0.000195	0.0154	CrCbGaD
Loxapine—Diazepam—ABCB1—melanoma	0.000186	0.0147	CrCbGaD
Loxapine—Clozapine—ABCB1—melanoma	0.000184	0.0145	CrCbGaD
Loxapine—CHRM2—Signaling Pathways—CTNNB1—melanoma	7.09e-06	1.22e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—TP53—melanoma	7.08e-06	1.22e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—MMP9—melanoma	7.08e-06	1.22e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—MYC—melanoma	7.08e-06	1.22e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—HRAS—melanoma	7.07e-06	1.22e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—CTNNB1—melanoma	7.07e-06	1.22e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—MMP9—melanoma	7.06e-06	1.22e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—CDKN1A—melanoma	7.05e-06	1.22e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—STAT3—melanoma	7.05e-06	1.22e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—MMP9—melanoma	7.04e-06	1.21e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—CDKN1A—melanoma	7.04e-06	1.21e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—PTEN—melanoma	7.04e-06	1.21e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—NRAS—melanoma	7.03e-06	1.21e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—PTEN—melanoma	7.02e-06	1.21e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—MMP9—melanoma	7.02e-06	1.21e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—CDKN1A—melanoma	7.01e-06	1.21e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—PIK3CA—melanoma	7.01e-06	1.21e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—MYC—melanoma	7.01e-06	1.21e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—VEGFA—melanoma	7.01e-06	1.21e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—NFKB1—melanoma	7e-06	1.21e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—PTEN—melanoma	7e-06	1.21e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—CDKN1A—melanoma	6.99e-06	1.21e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—NFKB1—melanoma	6.99e-06	1.21e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—HRAS—melanoma	6.98e-06	1.2e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling by GPCR—AKT1—melanoma	6.98e-06	1.2e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—PTEN—melanoma	6.98e-06	1.2e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—NFKB1—melanoma	6.96e-06	1.2e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—MAPK3—melanoma	6.96e-06	1.2e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CDKN1B—melanoma	6.95e-06	1.2e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—MMP9—melanoma	6.95e-06	1.2e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—NFKB1—melanoma	6.94e-06	1.2e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—STAT3—melanoma	6.94e-06	1.2e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—MMP9—melanoma	6.93e-06	1.2e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—CDKN1A—melanoma	6.92e-06	1.19e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—MAPK3—melanoma	6.92e-06	1.19e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—MAPK1—melanoma	6.92e-06	1.19e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—EGFR—melanoma	6.92e-06	1.19e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—NRAS—melanoma	6.92e-06	1.19e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—PTEN—melanoma	6.91e-06	1.19e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—CDKN1A—melanoma	6.9e-06	1.19e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—PTEN—melanoma	6.89e-06	1.19e-05	CbGpPWpGaD
Loxapine—ADRA2A—GPCR downstream signaling—AKT1—melanoma	6.88e-06	1.19e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—NFKB1—melanoma	6.87e-06	1.19e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—IL6—melanoma	6.87e-06	1.19e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—HRAS—melanoma	6.87e-06	1.18e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—IL6—melanoma	6.87e-06	1.18e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling by GPCR—AKT1—melanoma	6.86e-06	1.18e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—MAPK1—melanoma	6.86e-06	1.18e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—EGFR—melanoma	6.86e-06	1.18e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—NFKB1—melanoma	6.86e-06	1.18e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling by GPCR—AKT1—melanoma	6.85e-06	1.18e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling by GPCR—AKT1—melanoma	6.83e-06	1.18e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—IL6—melanoma	6.82e-06	1.18e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CASP3—melanoma	6.81e-06	1.18e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling by GPCR—AKT1—melanoma	6.81e-06	1.17e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—IL2—melanoma	6.8e-06	1.17e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—TP53—melanoma	6.78e-06	1.17e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—HRAS—melanoma	6.77e-06	1.17e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—IL6—melanoma	6.77e-06	1.17e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—MYC—melanoma	6.77e-06	1.17e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling by GPCR—AKT1—melanoma	6.74e-06	1.16e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—MAPK3—melanoma	6.73e-06	1.16e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—MYC—melanoma	6.73e-06	1.16e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling by GPCR—AKT1—melanoma	6.72e-06	1.16e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—PIK3CA—melanoma	6.68e-06	1.15e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—IL6—melanoma	6.68e-06	1.15e-05	CbGpPWpGaD
Loxapine—ADRA2C—Metabolism—PIK3CA—melanoma	6.65e-06	1.15e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CCND1—melanoma	6.63e-06	1.14e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—MAPK3—melanoma	6.63e-06	1.14e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—MAPK1—melanoma	6.62e-06	1.14e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—EGFR—melanoma	6.62e-06	1.14e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—PIK3CA—melanoma	6.59e-06	1.14e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—MAPK1—melanoma	6.59e-06	1.14e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—EGFR—melanoma	6.59e-06	1.14e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—IL6—melanoma	6.57e-06	1.13e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CTNNB1—melanoma	6.57e-06	1.13e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—MYC—melanoma	6.55e-06	1.13e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—KRAS—melanoma	6.54e-06	1.13e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—HRAS—melanoma	6.49e-06	1.12e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—IL6—melanoma	6.48e-06	1.12e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—KRAS—melanoma	6.48e-06	1.12e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—TP53—melanoma	6.46e-06	1.12e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—VEGFA—melanoma	6.46e-06	1.11e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—MYC—melanoma	6.45e-06	1.11e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—MMP9—melanoma	6.44e-06	1.11e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CDKN1A—melanoma	6.42e-06	1.11e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—MAPK1—melanoma	6.41e-06	1.11e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—EGFR—melanoma	6.41e-06	1.11e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—PTEN—melanoma	6.4e-06	1.1e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—STAT3—melanoma	6.39e-06	1.1e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—NRAS—melanoma	6.38e-06	1.1e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—TP53—melanoma	6.38e-06	1.1e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—NFKB1—melanoma	6.37e-06	1.1e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—VEGFA—melanoma	6.35e-06	1.1e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—VEGFA—melanoma	6.34e-06	1.09e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—AKT1—melanoma	6.34e-06	1.09e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—AKT1—melanoma	6.33e-06	1.09e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—VEGFA—melanoma	6.32e-06	1.09e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—MAPK1—melanoma	6.31e-06	1.09e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—EGFR—melanoma	6.3e-06	1.09e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—VEGFA—melanoma	6.3e-06	1.09e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—AKT1—melanoma	6.29e-06	1.09e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—STAT3—melanoma	6.29e-06	1.09e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—STAT3—melanoma	6.28e-06	1.08e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—NRAS—melanoma	6.28e-06	1.08e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—NRAS—melanoma	6.26e-06	1.08e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—STAT3—melanoma	6.26e-06	1.08e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—KRAS—melanoma	6.25e-06	1.08e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—AKT1—melanoma	6.24e-06	1.08e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—NRAS—melanoma	6.24e-06	1.08e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—VEGFA—melanoma	6.24e-06	1.08e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—STAT3—melanoma	6.24e-06	1.08e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—NRAS—melanoma	6.22e-06	1.07e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—VEGFA—melanoma	6.22e-06	1.07e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—KRAS—melanoma	6.22e-06	1.07e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—IL6—melanoma	6.21e-06	1.07e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—HRAS—melanoma	6.18e-06	1.07e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—STAT3—melanoma	6.18e-06	1.07e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—NRAS—melanoma	6.16e-06	1.06e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—AKT1—melanoma	6.16e-06	1.06e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—STAT3—melanoma	6.16e-06	1.06e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—NRAS—melanoma	6.15e-06	1.06e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—MAPK3—melanoma	6.11e-06	1.05e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—HRAS—melanoma	6.1e-06	1.05e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—AKT1—melanoma	6.06e-06	1.05e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—KRAS—melanoma	6.05e-06	1.04e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—MAPK3—melanoma	6.01e-06	1.04e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—PIK3CA—melanoma	6.01e-06	1.04e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—MAPK3—melanoma	6e-06	1.04e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—AKT1—melanoma	5.98e-06	1.03e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—MAPK3—melanoma	5.98e-06	1.03e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—MAPK3—melanoma	5.96e-06	1.03e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—KRAS—melanoma	5.96e-06	1.03e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—PIK3CA—melanoma	5.95e-06	1.03e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—MYC—melanoma	5.94e-06	1.03e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—IL6—melanoma	5.92e-06	1.02e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—MAPK3—melanoma	5.9e-06	1.02e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—MAPK3—melanoma	5.89e-06	1.02e-05	CbGpPWpGaD
Loxapine—CHRM3—Metabolism—PIK3CA—melanoma	5.89e-06	1.02e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—MYC—melanoma	5.85e-06	1.01e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—IL6—melanoma	5.84e-06	1.01e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—MYC—melanoma	5.83e-06	1.01e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—MYC—melanoma	5.82e-06	1e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—MAPK1—melanoma	5.81e-06	1e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—EGFR—melanoma	5.81e-06	1e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—TP53—melanoma	5.81e-06	1e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—MYC—melanoma	5.8e-06	1e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—VEGFA—melanoma	5.78e-06	9.98e-06	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—TP53—melanoma	5.76e-06	9.93e-06	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—PIK3CA—melanoma	5.75e-06	9.91e-06	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—MYC—melanoma	5.74e-06	9.91e-06	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—AKT1—melanoma	5.73e-06	9.88e-06	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—MYC—melanoma	5.73e-06	9.88e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—STAT3—melanoma	5.72e-06	9.88e-06	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—MAPK1—melanoma	5.72e-06	9.87e-06	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—EGFR—melanoma	5.72e-06	9.87e-06	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—PIK3CA—melanoma	5.72e-06	9.86e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—NRAS—melanoma	5.71e-06	9.85e-06	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—MAPK1—melanoma	5.71e-06	9.85e-06	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—EGFR—melanoma	5.71e-06	9.85e-06	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—MAPK1—melanoma	5.69e-06	9.82e-06	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—EGFR—melanoma	5.69e-06	9.82e-06	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—MAPK1—melanoma	5.67e-06	9.79e-06	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—EGFR—melanoma	5.67e-06	9.78e-06	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—MAPK1—melanoma	5.62e-06	9.69e-06	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—EGFR—melanoma	5.62e-06	9.69e-06	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—MAPK1—melanoma	5.6e-06	9.66e-06	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—EGFR—melanoma	5.6e-06	9.66e-06	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—PIK3CA—melanoma	5.56e-06	9.59e-06	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—TP53—melanoma	5.56e-06	9.59e-06	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—HRAS—melanoma	5.56e-06	9.59e-06	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—TP53—melanoma	5.53e-06	9.54e-06	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—HRAS—melanoma	5.51e-06	9.5e-06	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—KRAS—melanoma	5.49e-06	9.47e-06	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—PIK3CA—melanoma	5.47e-06	9.44e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—MAPK3—melanoma	5.47e-06	9.44e-06	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—AKT1—melanoma	5.46e-06	9.42e-06	CbGpPWpGaD
Loxapine—ADRA2C—Metabolism—AKT1—melanoma	5.43e-06	9.37e-06	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—KRAS—melanoma	5.4e-06	9.32e-06	CbGpPWpGaD
Loxapine—ADRA2A—Metabolism—PIK3CA—melanoma	5.4e-06	9.32e-06	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—KRAS—melanoma	5.39e-06	9.3e-06	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—AKT1—melanoma	5.39e-06	9.29e-06	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—TP53—melanoma	5.38e-06	9.28e-06	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—KRAS—melanoma	5.37e-06	9.27e-06	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—KRAS—melanoma	5.36e-06	9.24e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—MYC—melanoma	5.32e-06	9.18e-06	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—IL6—melanoma	5.32e-06	9.18e-06	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—HRAS—melanoma	5.32e-06	9.17e-06	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—KRAS—melanoma	5.3e-06	9.15e-06	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—TP53—melanoma	5.29e-06	9.13e-06	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—KRAS—melanoma	5.29e-06	9.13e-06	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—HRAS—melanoma	5.29e-06	9.12e-06	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—IL6—melanoma	5.27e-06	9.09e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—MAPK1—melanoma	5.2e-06	8.98e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—EGFR—melanoma	5.2e-06	8.98e-06	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—HRAS—melanoma	5.14e-06	8.88e-06	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—IL6—melanoma	5.09e-06	8.78e-06	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—HRAS—melanoma	5.06e-06	8.73e-06	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—IL6—melanoma	5.06e-06	8.73e-06	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—PIK3CA—melanoma	5.04e-06	8.7e-06	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—PIK3CA—melanoma	4.96e-06	8.56e-06	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—PIK3CA—melanoma	4.95e-06	8.55e-06	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—PIK3CA—melanoma	4.94e-06	8.52e-06	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—IL6—melanoma	4.92e-06	8.49e-06	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—PIK3CA—melanoma	4.92e-06	8.49e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—KRAS—melanoma	4.92e-06	8.48e-06	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—AKT1—melanoma	4.91e-06	8.47e-06	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—TP53—melanoma	4.88e-06	8.42e-06	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—PIK3CA—melanoma	4.87e-06	8.41e-06	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—AKT1—melanoma	4.86e-06	8.39e-06	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—PIK3CA—melanoma	4.86e-06	8.39e-06	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—IL6—melanoma	4.84e-06	8.36e-06	CbGpPWpGaD
Loxapine—CHRM3—Metabolism—AKT1—melanoma	4.81e-06	8.3e-06	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—TP53—melanoma	4.8e-06	8.29e-06	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—TP53—melanoma	4.79e-06	8.27e-06	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—TP53—melanoma	4.78e-06	8.24e-06	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—TP53—melanoma	4.76e-06	8.21e-06	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—TP53—melanoma	4.71e-06	8.13e-06	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—TP53—melanoma	4.7e-06	8.11e-06	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—AKT1—melanoma	4.69e-06	8.1e-06	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—AKT1—melanoma	4.67e-06	8.06e-06	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—HRAS—melanoma	4.67e-06	8.05e-06	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—HRAS—melanoma	4.59e-06	7.92e-06	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—HRAS—melanoma	4.58e-06	7.91e-06	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—HRAS—melanoma	4.57e-06	7.88e-06	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—HRAS—melanoma	4.55e-06	7.86e-06	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—AKT1—melanoma	4.54e-06	7.84e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—PIK3CA—melanoma	4.52e-06	7.79e-06	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—HRAS—melanoma	4.51e-06	7.78e-06	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—HRAS—melanoma	4.5e-06	7.76e-06	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—AKT1—melanoma	4.47e-06	7.71e-06	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—IL6—melanoma	4.47e-06	7.71e-06	CbGpPWpGaD
Loxapine—ADRA2A—Metabolism—AKT1—melanoma	4.41e-06	7.61e-06	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—IL6—melanoma	4.4e-06	7.58e-06	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—IL6—melanoma	4.39e-06	7.57e-06	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—IL6—melanoma	4.37e-06	7.54e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—TP53—melanoma	4.37e-06	7.54e-06	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—IL6—melanoma	4.36e-06	7.52e-06	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—IL6—melanoma	4.32e-06	7.45e-06	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—IL6—melanoma	4.3e-06	7.43e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—HRAS—melanoma	4.18e-06	7.21e-06	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—AKT1—melanoma	4.12e-06	7.11e-06	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—AKT1—melanoma	4.05e-06	7e-06	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—AKT1—melanoma	4.05e-06	6.98e-06	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—AKT1—melanoma	4.03e-06	6.96e-06	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—AKT1—melanoma	4.02e-06	6.94e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—IL6—melanoma	4e-06	6.9e-06	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—AKT1—melanoma	3.98e-06	6.87e-06	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—AKT1—melanoma	3.97e-06	6.85e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—AKT1—melanoma	3.69e-06	6.37e-06	CbGpPWpGaD
